Nephros Inc

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nephros Inc reports first profitable quarter, eyes growth opportunities

Nephros Inc delivered a strong performance in Q3 2024, achieving profitability and operational efficiency gains.
While facing revenue challenges and liquidity concerns, the company's strategic initiatives and focus on financial discipline position it for growth.
Opportunities in new markets and customer engagement through digital tools provide avenues for future expansion.
Balancing growth pursuits with financial prudence will be crucial for Nephros Inc's sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reports Full-Year Net Revenue of $10.4 Million, a 22% Year-Over-Year Increase and   Fourth Quarter Net Revenue of $2.8 Million, an 18% Year-Over-Year Increase; Reaffirms Fiscal Year 2022 Guidance of $13.0 Million to $13.5 Million in Annual Revenue

Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results

SOUTH ORANGE, NJ, Feb. 09, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it will file its fourth quarter financial results on Wednesday, February 23, 2022 after market close and will host a conference call that same day at 4:30 PM ET.

Nephros Fourth Quarter 2021 Financial Results Conference Call

SOUTH ORANGE, NJ, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today issued a 2022 letter to shareholders.

Nephros Issues 2022 Shareholder Letter

Anticipates Record Full-Year Net Revenue of $10.4 Million, a 21% Year-Over-Year Increase and Fourth Quarter Revenue of $2.8 Million, an 18% Year-Over-Year Increase; Provides 2022 Guidance of $13.0 Million to $13.5 Million in Annual Revenue

Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022

SOUTH ORANGE, NJ, Nov. 23, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced that Andy Astor, Chief Executive Officer of Nephros will be attending the Benchmark Company 10th Annual One-on-One Discovery Conference. The conference is taking place virtually on December 2, 2021, in a one-on-one and small group meeting format. The invitation-only event is for institutional clients of the Benchmark Company. For additional details, please contact Director of Corporate Access, Vince Curatola, at 414-203-5556.

Nephros to Present at the Benchmark Company 10th Annual One-on-One Discovery Conference

South Orange, New Jersey--(Newsfile Corp. - November 8, 2021) - Nephros, Inc. (NASDAQ: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced that Andy Astor, Chief Executive Officer of Nephros will be attending the Q4 Virtual Investor Summit. During the Presentation, Mr. Astor will provide an overview of the business and its growth prospects.Event: Q4 Investor SummitDate: November 16-17th, 2021Presentation: November 16th at 9:30 AM ETLocation: https://us06web.zoom.us

Nephros to Present at the Q4 Virtual Investor Summit

Nephros, Inc. (NEPH) CEO Andy Astor on Q3 2021 Results - Earnings Call Transcript

Nephros Inc. (NEPH) delivered earnings and revenue surprises of 0.00% and 0.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Nephros Inc. (NEPH) Reports Q3 Loss, Tops Revenue Estimates

Third Quarter Net Revenue of $2.6 Million Up 24% Year-Over-Year and 16% Quarter-over-Quarter

Nephros Announces Results for Quarter Ended September 30, 2021

SOUTH ORANGE, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire –   Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it will file its third quarter financial results on Thursday, November 4, 2021 after market close and will host a conference call that same day at 4:30 PM ET.

Nephros Announces Third Quarter 2021 Financial Results Conference Call

Anticipates Net Revenue of $2.6 Million, a 24% Year-Over-Year Increase

Nephros Announces Preliminary Results for Third Quarter of 2021

SOUTH ORANGE, NJ, Oct. 05, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced it has been selected to present at the  14 th  Annual LD Micro Main Event  on Tuesday, October 12, 2021 at 12:30 pm ET at the Luxe Sunset Bel-Air in Los Angeles. The Nephros presentation will be delivered by CEO, Andy Astor.

Nephros to Present at the LD Micro Main Event

SOUTH ORANGE, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced it has been selected to present at the 6th annual  MicroCap Leadership Summit on Friday, September 24th, 2021. The MicroCap Leadership Summit is a two-day virtual event hosted by MicroCapClub.

Nephros to Present at the Virtual MicroCap Leadership Summit

SOUTH ORANGE, NJ, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  Nephros, Inc.(Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced the appointment of Wes Lobo to the role of Chief Commercial Officer.

Nephros Appoints Wes Lobo to Chief Commercial Officer

Nephros, Inc. (NEPH) CEO Andrew Astor on Q2 2021 Results - Earnings Call Transcript

Second Quarter Net Revenue of $2.3 Million; 44% Year-Over-Year Increase; Strategic Acquisition of GenArraytion, Inc.; HDF Product Submitted to FDA for 510(k) Clearance

Nephros Announces Results for Quarter Ended June 30, 2021

Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Nephros Inc. (NEPH) Report Negative Q2 Earnings? What You Should Know

Strategic Acquisition Accelerates Pathogen Detection Product Development

Nephros Announces Acquisition of GenArraytion, Inc.

SOUTH ORANGE, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, has been invited to present at the Access to Giving Virtual Investor conference, which is being held July 13-15.

Nephros CEO Presenting at Access to Giving Virtual Investor Conference

Nephros Inc (NASDAQ: NEPH) has announced preliminary results and expects Q2 sales of approximately $2.2 million, representing a Y/Y increase of 40%  "Revenue growth seems to be returning to pre-pandemic levels. In addition, revenue for the six months ended June 30, 2021, is expected to be over $5 million, a 20% increase over the same periods in 2020 and 2019, which we believe puts us in a strong position going into the second half of the year", said CEO Andy Astor.

Nephros Sees 40% Increase In Q2 Sales, Submits HDF Product For FDA Approval

Anticipates Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase; Submits HDF Product to FDA for 510(k) Clearance

Nephros Announces Preliminary Results for Second Quarter of 2021

Nephros Inc. (NEPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Here's What Could Help Nephros Inc. (NEPH) Maintain Its Recent Price Strength

Nephros Inc. (NEPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

What Makes Nephros Inc. (NEPH) a Good Fit for "Trend Investing"

As a small operator, Nephros has been making big waves in various industries that are facing tailwinds. They include water filtration, hemodialysis, and pathogen detection. After 15 consecutive quarters of top-line growth, Nephros growth is stabilized due to COVID constraints.

Nephros: Huge Growth In A Tiny Stock

Nephros, Inc. (NEPH) CEO Andy Astor on Q1 2021 Results - Earnings Call Transcript

News for Nephros Inc Stock (NEPH)